載入...
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?
Waiting for a definite answer from well-designed randomized prospective clinical trials, the impact of the new antiobesity drugs -liraglutide, bupropion/naltrexone, phentermine/topiramate and lorcaserin- on cardiovascular outcomes remains uncertain. What has been learned from previous experience wit...
Na minha lista:
| 發表在: | Int J Obes Suppl |
|---|---|
| Main Authors: | , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group UK
2020
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7371629/ https://ncbi.nlm.nih.gov/pubmed/32714509 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41367-020-0015-3 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|